Molecular Partners received a European Small and Mid-Cap Award
Zurich-Schlieren, December 10, 2015. Molecular Partners AG (MOLN) announced today that the company has achieved a top 3 ranking in the category “Most Innovative Newcomer” at the European Small and Mid-Cap Awards 2015 in Brussels. This annual awards ceremony recognizes the best European small and mid-sized companies who have gained access to capital markets via an Initial Public Offering.
Organized by the European Commission’s Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs, in cooperation with European Issuers and the Federation of European Securities Exchanges (FESE), the European Small and Mid-Cap Awards promote best practices and success stories of the most dynamic companies listed on the European public capital markets. The awards were launched in 2013 with the aim of encouraging companies to access Europe’s capital markets.
“We are very proud about the award we received and we thank our shareholders for their ongoing trust and support,” said Christian Zahnd, Chief Executive Officer of Molecular Partners. “International capital markets have generously provided Molecular Partners with the resources necessary to advance our innovative DARPin technology and our pipeline of novel therapeutics for the treatment of serious diseases. Our private and public investors and the SIX Swiss Exchange have been truly supportive partners to our company in the year since we have been public and we are honored to share this award with you.”
Christoph Landis, Division CEO of SIX Swiss Exchange, commented: “We would like to congratulate Molecular Partners, a company listed on SIX Swiss Exchange, for their performance in finishing in the top 3 companies. As the leading stock exchange in Europe for the life science segment, we are delighted to have been able to provide advisory to Molecular Partners during their IPO and as they now enjoy the success of being public. We wish them all the very best for the future.”
Additional information on the European Small and Mid-Cap Awards 2015 is available at: www.fese.eu.
About Molecular Partners AG
Molecular Partners is a clinical-stage biopharmaceutical company that is developing a new powerful class of therapies known as DARPins. DARPins are potent, specific, and versatile small-protein therapies, which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin technology has the potential to offer a multi-specific approach to treatment, which enables DARPins to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPins have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders.
Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company has ongoing research and development partnerships with leading pharmaceutical companies, including Allergan and Janssen, and is backed by established biotech investors. For more information regarding Molecular Partners, go to: www.molecularpartners.com.
For further details please contact:
Dr. Christian Zahnd, CEO
Andreas Emmenegger, CFO
Tel: +41 (0) 44 755 77 00
Tel: +41 (0) 43 344 42 42
Tel: +44 (0) 208 877 8400
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements, assessments or intentions.